Clinical Trials Logo

Lymphoma, B-Cell, Marginal Zone clinical trials

View clinical trials related to Lymphoma, B-Cell, Marginal Zone.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04508647 Completed - Follicular Lymphoma Clinical Trials

Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

Start date: November 23, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, Phase II interventional study in order to assess efficacy and safety of single agent ublituximab as initial therapy for FL (Follicular lymphoma) and MZL (Marginal zone lymphoma ) with response driven addition of umbralisib for suboptimal response.

NCT ID: NCT04465162 Completed - Clinical trials for Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Start date: June 7, 2000
Phase: Phase 2
Study type: Interventional

This trial studies the side effects of radiation therapy used alone, and if it can achieve a high cure rate in the treatment of patients with MALT lymphoma. Radiation therapy uses high energy sources to kill cancer cells and shrink tumors. This treatment may improve the patient's lymphoma.

NCT ID: NCT04298879 Completed - Clinical trials for Indolent Non-hodgkin Lymphoma

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Start date: April 7, 2020
Phase: Phase 2
Study type: Interventional

A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

NCT ID: NCT03846427 Completed - Clinical trials for Marginal Zone Lymphoma

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

MAGNOLIA
Start date: February 19, 2019
Phase: Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).

NCT ID: NCT03797456 Completed - MZL Clinical Trials

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 110 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

NCT ID: NCT03520920 Completed - Follicular Lymphoma Clinical Trials

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Start date: January 4, 2018
Phase: Phase 2
Study type: Interventional

This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (non-GCB [non-germinal center B-cell-like] subtype) and R/R indolent lymphoma (follicular lymphoma [FL] and marginal zone lymphoma [MZL]).

NCT ID: NCT03364231 Completed - Clinical trials for Marginal Zone Lymphoma

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

NCT ID: NCT03276468 Completed - Follicular Lymphoma Clinical Trials

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts: - relapsed/refractory follicular lymphoma (FL) patients - relapsed/refractory aggressive (DLBCL) lymphoma patients - relapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)

NCT ID: NCT03219723 Completed - Clinical trials for Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Start date: September 1, 2015
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.

NCT ID: NCT02950220 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: January 12, 2017
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of ibrutinib when given together with pembrolizumab and to see how well they work in treating patients with non-Hodgkin lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Given pembrolizumab and ibrutinib may work better in treating patients with non-Hodgkin lymphoma.